Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

The amount of activity, both in development and in commercialized technology, in the field of cell therapy and tissue engineering has been enormous in the past few years, stemming from advances in stem cell therapy and cell biology in general.  One should not be surprised to see the number of active companies and products in this area.

If one were to examine a narrow niche in cell therapy and tissue engineering, such as in cardiology and cardiovasular applications, one might nonetheless be startled at the specific activity.  See below

Source: MedMarket Diligence, LLC; Report #S520.

In the 2010 MedMarket Diligence report #S520, “Tissue Engineering, Cell Therapy and Transplantation Worldwide”, we detailed the technology, product, company and market activity of the spectrum of cell/tissue developments. Highlighting only cardiology/cardiovascular, above, gives evidence to the size of the broader market.

It seems that many stakeholders in companies at the early stages of development in this field generally do not recognize the extent to which this is a current, active market of available products, not some basic research (e.g., biotech “industry”) in which billions of dollars change hands (from VC to entrepreneurs) with little coming back in clinically approved product revenue.  An even larger volume of technology that, while it may not have been approved yet, is deep in the process of seeking approval. It was for this reason that we were able to definitively characterize this $6.9 billion global market, forecast to exceed $30 billion by 2018.

bookmark to

Read More: http://feedproxy.google.com/~r/AdvancedMedicalTechnologies/~3/IVmXVTzh760/